secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001711279-26-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates
--------------------------------------------------------------------------------

- VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.
- Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.
- FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.
- KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.
- FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/krys-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer